 SAN FRANCISCO and SUZHOU, China, April 13, 2021 GLOBE NEWSWIRE -- Adagene Inc. Adagene Nasdaq: ADAG, a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced updated preclinical data from its lead SAFEbodyTM program, ADG126, are being presented at the American Association for Cancer Research AACR Annual Meeting 2021. 